203 related articles for article (PubMed ID: 33507835)
1. Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
Dahlke F; Arnold DL; Aarden P; Ganjgahi H; Häring DA; Čuklina J; Nichols TE; Gardiner S; Bermel R; Wiendl H
Mult Scler; 2021 Nov; 27(13):2062-2076. PubMed ID: 33507835
[TBL] [Abstract][Full Text] [Related]
2. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
3. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
6. [Current questions of multiple sclerosis: the secunder progressive form of the disease].
Vécsei L
Ideggyogy Sz; 2020 Jan; 73(1-2):7-14. PubMed ID: 32057199
[TBL] [Abstract][Full Text] [Related]
7. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
[TBL] [Abstract][Full Text] [Related]
10. Impact of Age on Multiple Sclerosis Disease Activity and Progression.
Zeydan B; Kantarci OH
Curr Neurol Neurosci Rep; 2020 May; 20(7):24. PubMed ID: 32458308
[TBL] [Abstract][Full Text] [Related]
11. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
12. A national registry-based study of ethnic differences in people with multiple sclerosis in Iran.
Ashtari F; Kavosh A; Baghbanian SM; Hosseini Nejad Mir N; Hosseini S; Razazian N; Majdinasab N; Farajzadegan Z; Shaygannejad V; Adibi I; Eskandarieh S; Sahraian MA
Clin Neurol Neurosurg; 2024 Apr; 239():108216. PubMed ID: 38490075
[TBL] [Abstract][Full Text] [Related]
13. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.
Mina Y; Azodi S; Dubuche T; Andrada F; Osuorah I; Ohayon J; Cortese I; Wu T; Johnson KR; Reich DS; Nair G; Jacobson S
Neuroimage Clin; 2021; 30():102680. PubMed ID: 34215150
[TBL] [Abstract][Full Text] [Related]
14. Gray matter atrophy is related to long-term disability in multiple sclerosis.
Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH
Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
16. Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.
Stone LA; Cutter GR; Fisher E; Richert N; McCartin J; Ohayon J; Bash C; McFarland H
J Neuroimaging; 2016 May; 26(3):296-302. PubMed ID: 26686343
[TBL] [Abstract][Full Text] [Related]
17. Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis.
Sestito C; Leurs CE; Steenwijk MD; Brevé JJP; Twisk JWR; Wilhelmus MMM; Drukarch B; Teunissen CE; van Dam AM; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33906937
[TBL] [Abstract][Full Text] [Related]
18. Brain atrophy and lesion load predict long term disability in multiple sclerosis.
Popescu V; Agosta F; Hulst HE; Sluimer IC; Knol DL; Sormani MP; Enzinger C; Ropele S; Alonso J; Sastre-Garriga J; Rovira A; Montalban X; Bodini B; Ciccarelli O; Khaleeli Z; Chard DT; Matthews L; Palace J; Giorgio A; De Stefano N; Eisele P; Gass A; Polman CH; Uitdehaag BM; Messina MJ; Comi G; Filippi M; Barkhof F; Vrenken H;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1082-91. PubMed ID: 23524331
[TBL] [Abstract][Full Text] [Related]
19. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
[TBL] [Abstract][Full Text] [Related]
20. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
